Vanguard Group’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $36.3M | Buy |
2,301,794
+362,965
| +19% | +$4.61M | ﹤0.01% | 2339 |
|
|
2025
Q3 | $23.2M | Sell |
1,938,829
-37,843
| -2% | -$302K | ﹤0.01% | 2549 |
|
|
2025
Q2 | $14.9M | Sell |
1,976,672
-30,761
| -2% | -$185K | ﹤0.01% | 2702 |
|
|
2025
Q1 | $11.1M | Buy |
2,007,433
+23,269
| +1% | +$144K | ﹤0.01% | 2788 |
|
|
2024
Q4 | $11.4M | Buy |
1,984,164
+2,298
| +0.1% | +$22K | ﹤0.01% | 2883 |
|
|
2024
Q3 | $20.5M | Buy |
1,981,866
+47,476
| +2% | +$621K | ﹤0.01% | 2584 |
|
|
2024
Q2 | $25.1M | Buy |
1,934,390
+6,312
| +0.3% | +$85.2K | ﹤0.01% | 2455 |
|
|
2024
Q1 | $33.7M | Buy |
1,928,078
+134,292
| +7% | +$1.78M | ﹤0.01% | 2343 |
|
|
2023
Q4 | $16.9M | Buy |
1,793,786
+133,266
| +8% | +$1.24M | ﹤0.01% | 2673 |
|
|
2023
Q3 | $18.5M | Sell |
1,660,520
-45,655
| -3% | -$735K | ﹤0.01% | 2576 |
|
|
2023
Q2 | $36.5M | Buy |
1,706,175
+169,272
| +11% | +$4.99M | ﹤0.01% | 2330 |
|
|
2023
Q1 | $62.2M | Buy |
1,536,903
+14,714
| +1% | +$703K | ﹤0.01% | 2071 |
|
|
2022
Q4 | $70.8M | Buy |
1,522,189
+45,279
| +3% | +$2.06M | ﹤0.01% | 1991 |
|
|
2022
Q3 | $76.6M | Sell |
1,476,910
-39,779
| -3% | -$2.32M | ﹤0.01% | 1954 |
|
|
2022
Q2 | $71.7M | Sell |
1,516,689
-72,535
| -5% | -$3.94M | ﹤0.01% | 2006 |
|
|
2022
Q1 | $113M | Sell |
1,589,224
-36,685
| -2% | -$2.39M | ﹤0.01% | 1871 |
|
|
2021
Q4 | $122M | Sell |
1,625,909
-174,454
| -10% | -$13.7M | ﹤0.01% | 1881 |
|
|
2021
Q3 | $102M | Sell |
1,800,363
-56,656
| -3% | -$2.8M | ﹤0.01% | 1964 |
|
|
2021
Q2 | $81.7M | Sell |
1,857,019
-41,655
| -2% | -$2.04M | ﹤0.01% | 2108 |
|
|
2021
Q1 | $93.6M | Buy |
1,898,674
+98,095
| +5% | +$4.89M | ﹤0.01% | 1981 |
|
|
2020
Q4 | $75.8M | Buy |
1,800,579
+79,689
| +5% | +$3.51M | ﹤0.01% | 1979 |
|
|
2020
Q3 | $78.8M | Buy |
1,720,890
+30,093
| +2% | +$1.46M | ﹤0.01% | 1803 |
|
|
2020
Q2 | $84.9M | Buy |
1,690,797
+537
| +0% | +$27.8K | ﹤0.01% | 1754 |
|
|
2020
Q1 | $86.9M | Sell |
1,690,260
-7,469
| -0.4% | -$398K | ﹤0.01% | 1604 |
|
|
2019
Q4 | $105M | Buy |
1,697,729
+10,881
| +0.6% | +$675K | ﹤0.01% | 1727 |
|
|
2019
Q3 | $101M | Buy |
1,686,848
+66,198
| +4% | +$4.92M | ﹤0.01% | 1717 |
|
|
2019
Q2 | $137M | Sell |
1,620,650
-2,641
| -0.2% | -$238K | 0.01% | 1582 |
|
|
2019
Q1 | $155M | Buy |
1,623,291
+97,457
| +6% | +$8.74M | 0.01% | 1504 |
|
|
2018
Q4 | $108M | Buy |
1,525,834
+99,043
| +7% | +$7.59M | ﹤0.01% | 1636 |
|
|
2018
Q3 | $122M | Buy |
1,426,791
+330,374
| +30% | +$33.1M | ﹤0.01% | 1703 |
|
|
2018
Q2 | $127M | Buy |
1,096,417
+230,026
| +27% | +$23M | 0.01% | 1656 |
|
|
2018
Q1 | $70.1M | Buy |
866,391
+44,704
| +5% | +$3.44M | ﹤0.01% | 1897 |
|
|
2017
Q4 | $48.2M | Sell |
821,687
-15,876
| -2% | -$795K | ﹤0.01% | 2076 |
|
|
2017
Q3 | $39.2M | Sell |
837,563
-9,458
| -1% | -$380K | ﹤0.01% | 2162 |
|
|
2017
Q2 | $30.5M | Buy |
847,021
+54,856
| +7% | +$1.75M | ﹤0.01% | 2266 |
|
|
2017
Q1 | $24.4M | Buy |
792,165
+53,007
| +7% | +$1.65M | ﹤0.01% | 2367 |
|
|
2016
Q4 | $24.8M | Buy |
739,158
+42,281
| +6% | +$1.21M | ﹤0.01% | 2326 |
|
|
2016
Q3 | $18.5M | Buy |
696,877
+46,317
| +7% | +$1.08M | ﹤0.01% | 2394 |
|
|
2016
Q2 | $14.3M | Buy |
650,560
+19,071
| +3% | +$499K | ﹤0.01% | 2477 |
|
|
2016
Q1 | $18.5M | Buy |
631,489
+15,461
| +3% | +$430K | ﹤0.01% | 2333 |
|
|
2015
Q4 | $20.3M | Buy |
616,028
+42,348
| +7% | +$1.38M | ﹤0.01% | 2301 |
|
|
2015
Q3 | $20.7M | Buy |
573,680
+265,798
| +86% | +$11.4M | ﹤0.01% | 2279 |
|
|
2015
Q2 | $13.9M | Buy |
307,882
+23,406
| +8% | +$910K | ﹤0.01% | 2513 |
|
|
2015
Q1 | $8.71M | Buy |
284,476
+21,030
| +8% | +$818K | ﹤0.01% | 2707 |
|
|
2014
Q4 | $13.4M | Buy |
263,446
+21,186
| +9% | +$949K | ﹤0.01% | 2415 |
|
|
2014
Q3 | $9.59M | Buy |
242,260
+62,350
| +35% | +$2.49M | ﹤0.01% | 2514 |
|
|
2014
Q2 | $7.75M | Buy |
179,910
+12,279
| +7% | +$468K | ﹤0.01% | 2634 |
|
|
2014
Q1 | $6.7M | Buy |
167,631
+118,512
| +241% | +$4.3M | ﹤0.01% | 2683 |
|
|
2013
Q4 | $1.34M | Buy |
49,119
+18,489
| +60% | +$448K | ﹤0.01% | 3334 |
|
|
2013
Q3 | $702K | Sell |
30,630
-196
| -0.6% | -$3.75K | ﹤0.01% | 3463 |
|
|
2013
Q2 | $546K | Buy |
+30,826
| New | +$601K | ﹤0.01% | 3452 |
|
Other funds holding ENTA
FCM
KAM
DTC
Vanguard Group's ENTA Position: Q4 2025 in Review
Vanguard Group increased its Enanta Pharmaceuticals (ENTA) stake by 19% in Q4 2025, buying an estimated $4.61M and bringing the position to 2,301,794 shares worth $36.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2339.
Vanguard Group first reported a position in ENTA in Q2 2013 and has held it in 51 quarters since. The position peaked at $155M in Q1 2019. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.
- Vanguard Group held 2,301,794 shares of Enanta Pharmaceuticals worth $36.3M as of Q4 2025.
- Vanguard Group bought 362,965 Enanta Pharmaceuticals shares in Q4 2025, an estimated $4.61M.
- Enanta Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2339 holding.
- Vanguard Group first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Enanta Pharmaceuticals position peaked at $155M in Q1 2019.
- 131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.